Neuromeningeal Tuberculosis in a Patient with Rheumatoid Arthritis Previously Exposed to Ineffective Etanercept Therapy and Revealed by Infliximab: Figure 1
Open Access
- 9 February 2010
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (2), 471
- https://doi.org/10.3899/jrheum.090241
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infectionArthritis Care & Research, 2007
- Does anti-tumour necrosis factor treatment modify the tuberculin PPD response?Annals Of The Rheumatic Diseases, 2006
- Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsArthritis & Rheumatism, 2005
- Tumor Necrosis Factor Blockers and Reactivation of Latent TuberculosisClinical Infectious Diseases, 2004
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentThe New England Journal of Medicine, 2001
- Diagnosis of Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10Clinical and Diagnostic Laboratory Immunology, 2000